| Issue Date | Title | Author(s) | Source | WOS | Fulltext/Archive link |
| 2015 | The performance characteristics of inclined highly pervious pipe breakwaters | Ruey-Syan Shih ; Wen-Kai Weng ; Chung-Ren Chou | Ocean Engineering | 12 | |
| 2016 | Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation | Muffly, L. S.; Sheehan, K.; Armstrong, R.; Tate, K.; Tudisco, C.; Rezvani, A. R.; Miklos, D.; Arai, S.; Shizuru, J.; Johnston, L.; Meyer, E.; Wen-Kai Weng ; Laport, G. G.; Negrin, R. S.; Strober, S.; Lowsky, R. | Blood | | |
| 2015 | Phase I/II Clinical Trial of CpG-Activated Whole Cell Vaccine in Mantle Cell Lymphoma (MCL): Results in Safety and Efficacy from Planned Interim Analysis | Chu, M. P.; Brody, J.; Kohrt, H. E.; Frank, M. J.; Khodadoust, M.; Reddy, S.; Advani, R. H.; Gupta, N. K.; Laport, G.; Maeda, L. S.; Meyer, E.; Miklos, D. B.; Negrin, R.; Rezvani, A. R.; Wen-Kai Weng ; Sheehan, K.; Faham, M.; Czerwinski, D. K.; Okada, A.; Levy, R. | Blood | | |
| 2018 | Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells | Meyer, E.; Laport, G. G.; Tantsura, I.; Tang, S. W.; Sahaf, B.; Rangarajan, K.; Armstrong, R.; Tate, K.; Tudisco, C.; Sheehan, K.; Arai, S.; Johnston, L.; Muffly, L.; Lowsky, R.; Rezvani, A.; Wen-Kai Weng ; Miklos, D.; Negrin, R. S. | Biology of Blood and Marrow Transplantation | | |
| 2008 | Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma | Arai, S.; Letsinger, R.; Johnston, L.; Laport, G.; Lowsky, R.; Miklos, D.; Shizuru, J.; Wen-Kai Weng ; Wong, R.; Lavori, P.; Blume, K.; Negrin, R.; Horning, S. | Blood | | |
| 2010 | Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma | Arai, S.; Letsinger, R.; Wong, R. M.; Johnston, L. J.; Laport, G. G.; Lowsky, R.; Miklos, D. B.; Shizuru, J. A.; Wen-Kai Weng ; Lavori, P. W.; Blume, K. G.; Negrin, R. S.; Horning, S. J. | Biology of Blood and Marrow Transplantation | | |
| 2015 | Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sezary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project | Kim, Y. H.; Tavallaee, M.; Sundram, U.; Salva, K. A.; Wood, G. S.; Li, S. F.; Rozati, S.; Nagpal, S.; Krathen, M.; Reddy, S.; Hoppe, R. T.; Nguyen-Lin, A.; Wen-Kai Weng ; Armstrong, R.; Pulitzer, M.; Advani, R. H.; Horwitz, S. M. | Journal of Clinical Oncology | | |
| 2015 | A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia | Strati, P.; Tong, W. G.; Vitale, C.; Wierda, W. G.; O'Brien, S.; Brown, J. R.; Wen-Kai Weng ; Kipps, T.; Keating, M. J.; Ferrajoli, A. | Leukemia & Lymphoma | | |
| 2005 | A polymorphism in the C1qA component of complement correlates with prolonged complete remission following rituximab therapy of follicular lymphoma | Racila, E.; Wen-Kai Weng ; Wooldridge, J. E.; Link, B. K.; Levy, R.; Weiner, G. J. | Blood | | |
| 2008 | A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma | Racila, E.; Link, B. K.; Wen-Kai Weng ; Witzig, T. E.; Ansell, S.; Maurer, M. J.; Huang, J.; Dahle, C.; Halwani, A.; Levy, R.; Weiner, G. J. | Clinical Cancer Research | | |
| 2018 | Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sezary Syndrome | Dai, J.; Almazan, T. H.; Hong, E. K.; Khodadoust, M. S.; Arai, S.; Wen-Kai Weng ; Kim, Y. H. | Jama Dermatology | | |
| 2007 | The prediction of the dynamic and structural motions of a floating-pier system in waves | Lee, H. H.; Chen, L. Y.; Wen-Kai Weng ; Shyue, S. W. | Ocean Engineering | | |
| 2012 | Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence | Arai, S.; Sahaf, B.; Narasimhan, B.; Chen, G. L.; Jones, C. D.; Lowsky, R.; Shizuru, J. A.; Johnston, L. J.; Laport, G. G.; Wen-Kai Weng ; Benjamin, J. E.; Schaenman, J.; Brown, J.; Ramirez, J.; Zehnder, J. L.; Negrin, R. S.; Miklos, D. B. | Blood | | |
| 2008 | Prophylactic Rituximab after Reduced Intensity Conditioning Transplantation Results in Low Chronic Gvhd | Arai, S.; Sahaf, B.; Jones, C.; Zhender, J.; Lowsky, R.; Strober, S.; Shizuru, J.; Negrin, R.; Johnston, L.; Laport, G.; Schaenman, J.; Brown, J.; Wen-Kai Weng ; Letsinger, R.; Wong, R.; Lavori, P.; Miklos, D. | Blood | | |
| 2011 | A prospective trial of low-dose total skin electron beam therapy in mycosis fungoides and proposal of a new clinically meaningful endpoint | Bashey, S.; Harrison, C.; Navi, D.; Lingala, B.; Armstrong, R.; Wen-Kai Weng ; Sundram, U.; Kim, Y. H.; Hoppe, R. | Journal Der Deutschen Dermatologischen Gesellschaft | | |
| 2022 | Relative Energy Variation Characteristics Considering Interaction between Waves and Vegetation Structure | Shih, Ruey-Syan ; Li, Chi-Yu ; Weng, Wen-Kai ; Lin, Chih-Hung | WATER-SUI | 0 | |
| 2012 | RETRACTED: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer (Retracted article. See vol. 129, pg. 2595, 2019) | Kohrt, H. E.; Houot, R.; Weiskopf, K.; Goldstein, M. J.; Scheeren, F.; Czerwinski, D.; Colevas, A. D.; Wen-Kai Weng ; Clarke, M. F.; Carlson, R. W.; Stockdale, F. E.; Mollick, J. A.; Chen, L. P.; Levy, R. | Journal of Clinical Investigation | | |
| 2014 | RETRACTED: Targeting CD137 enhances the efficacy of cetuximab (Retracted article. See vol. 129, pg. 2595, 2019) | Kohrt, H. E.; Colevas, A. D.; Houot, R.; Weiskopf, K.; Goldstein, M. J.; Lund, P.; Mueller, A.; Sagiv-Barfi, I.; Marabelle, A.; Lira, R.; Troutner, E.; Richards, L.; Rajapaska, A.; Hebb, J.; Chester, C.; Waller, E.; Ostashko, A.; Wen-Kai Weng ; Chen, L. P.; Czerwinski, D.; Fu, Y. X.; Sunwoo, J.; Levy, R. | Journal of Clinical Investigation | | |
| 2019 | RETRACTION: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer (Retraction of Vol 122, Pg 1066, 2012) | Kohrt, H. E.; Houot, R.; Weiskopf, K.; Goldstein, M. J.; Scheeren, F.; Czerwinski, D.; Colevas, A. D.; Wen-Kai Weng ; Clarke, M. F.; Carlson, R. W.; Stockdale, F. E.; Mollick, J. A.; Chen, L. P.; Levy, R. | Journal of Clinical Investigation | | |
| 2019 | RETRACTION: Targeting CD137 enhances the efficacy of cetuximab (Retraction of Vol 124, Pg 2668, 2014) | Kohrt, H. E.; Colevas, A. D.; Houot, R.; Weiskopf, K.; Goldstein, M. J.; Lund, P.; Mueller, A.; Sagiv-Barfi, I.; Marabelle, A.; Lira, R.; Troutner, E.; Richards, L.; Rajapaska, A.; Hebb, J.; Chester, C.; Waller, E.; Ostashko, A.; Wen-Kai Weng ; Chen, L. P.; Czerwinski, D.; Fu, Y. X.; Sunwoo, J.; Levy, R. | Journal of Clinical Investigation | | |
